Listen

Press releases

Receive e-mail alerts

Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
mai 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results
mai 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
mai 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
mai 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
avril 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results
mars 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
décembre 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results
novembre 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
novembre 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
septembre 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
septembre 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
septembre 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results
août 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
août 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
juillet 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results
mai 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
mai 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May
avril 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
avril 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
mars 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
mars 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences
mars 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
février 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
décembre 22, 2022 at 11:15 AM UTC
Internal link Lilly and ProQR to Expand RNA Editing Collaboration
décembre 22, 2022 at 11:00 AM UTC

Press releases

Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

Internal link ProQR Announces First Quarter 2025 Operating and Financial Results

Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Internal link ProQR Announces Year End 2024 Operating and Financial Results

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results

Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets

Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results

Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

Internal link ProQR Announces First Quarter 2023 Operating and Financial Results

Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

Internal link ProQR Announces Upcoming Investor Conferences in April and May

Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

Internal link ProQR to Present at Upcoming Scientific and Industry Conferences

Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023

Internal link ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

Internal link Lilly and ProQR to Expand RNA Editing Collaboration